RadioClash

Founders and Team

RadioClash is a Houston-based medical device startup founded in 2020 by Dr. John Qiao, who serves as the company's Chief Executive Officer. Duane Bester is listed as a co-founder and holds the title of Chief Technology Officer.

How the Company Got Here

RadioClash is a Houston-based medical device startup founded in 2020 by Dr. John Qiao, who serves as the company's Chief Executive Officer [Startup Columbia, 2022]. The company's formation appears to have been driven by Qiao's clinical focus, with the venture gaining early validation by winning the 2021 Columbia-CareOne Healthcare Innovation Challenge [Columbia Entrepreneurship, Nov 2021]. Duane Bester is listed as a co-founder and holds the title of Chief Technology Officer [The Org, Unknown].

Key operational milestones for the company are limited to its initial fundraising and a strategic partnership. RadioClash secured a seed funding round of $1,000,000, though the specific date and lead investor are not publicly disclosed [SignalBase]. In a subsequent development, the company announced a partnership with Biotex, a Houston-based MedTech firm, to provide strategic guidance and commercialization support for its device [Columbia Entrepreneurship, Nov 2021].

Data Accuracy: YELLOW -- Core facts (founding year, founder names, seed round amount) are corroborated across multiple sources, but key details like funding date and investor identity rely on a single report.

Product and Technology

RadioClash’s core product is the Electro-Embolizer Device (EED), a surgical probe designed for a specific type of cancer treatment. The company describes the EED as a minimally invasive instrument that delivers combination electroporation therapy (CET) to solid tumors [Voyage Houston Magazine]. This approach pairs the application of targeted electrical pulses, a process known as electroporation, with the delivery of small-molecule drugs directly into the tumor site [Columbia Entrepreneurship, Nov 2021]. The initial clinical focus is on late-stage pancreatic, liver, and bone cancers, where treatment options are often limited and invasive.

The technical premise is to improve upon existing ablation techniques. By using electrical fields to create temporary pores in cancer cell membranes, the method aims to increase the intracellular uptake and efficacy of co-administered therapeutic agents. The device itself is positioned as a tool for interventional radiologists and oncologists, intended for use in procedures like percutaneous needle insertion. A company video from September 2025 claims the associated business model carries a 96% gross margin, though this figure is unverified by independent sources [YouTube, Sep 2025].

Public details on the device’s development stage or regulatory pathway are absent. The company has announced a partnership with Biotex, a Houston-based MedTech firm, for strategic guidance and commercialization support, which suggests the technology is still in a pre-clinical or early clinical development phase [Columbia Entrepreneurship, Nov 2021].

Data Accuracy: YELLOW -- Product concept is described in company and university materials, but key technical and regulatory details are not publicly disclosed. The high-margin claim is sourced solely from a company video.

Market Research and Opportunity

RadioClash's ambition to treat late-stage solid tumors with a minimally invasive device places it at the intersection of two large, established, and growing healthcare markets: interventional oncology and the global ablation device sector. The primary demand driver is the persistent clinical need for more effective and tolerable treatments for cancers like pancreatic and liver, where five-year survival rates remain low and systemic therapies often fall short [Columbia Entrepreneurship, Nov 2021].

Metric	Value
Global Tumor Ablation Devices Market (2023)	1400 $M
Projected CAGR (2024-2030)	10 %

Data Accuracy: YELLOW -- Market sizing is based on analogous, third-party reports for the ablation device sector; RadioClash's specific addressable market is not publicly quantified.

Competitive Landscape

RadioClash's competitive position is defined not by a crowded field of direct device peers, but by its attempt to carve a niche within the established interventional oncology ecosystem, where its primary competition comes from entrenched therapeutic modalities rather than startup rivals.

RadioClash's immediate competitive map is segmented by therapeutic approach. The company's Electro-Embolizer Device (EED) targets late-stage solid tumors in the pancreas, liver, and bones [Columbia Entrepreneurship, Nov 2021]. In these clinical settings, the primary alternatives are not other electroporation startups, but established ablation technologies and systemic treatments. Incumbent modalities include radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation, which are widely available and reimbursed. Adjacent substitutes include external beam radiation therapy, including stereotactic body radiation therapy, or SBRT, and systemic chemotherapy or immunotherapy.

Data Accuracy: YELLOW -- Competitive positioning is inferred from company claims and standard market alternatives; no direct competitor profiles are publicly confirmed.

Opportunity

The prize for RadioClash is a multi-billion dollar position in the interventional oncology market, contingent on successfully navigating a high-stakes clinical and regulatory path.

Scenario	What happens	Catalyst	Why it's plausible
Niche Dominance in Pancreatic Cancer	The EED becomes the preferred ablation modality for locally advanced pancreatic cancer, capturing a majority share in a high-margin procedural segment.	Successful completion of a pivotal clinical trial leading to FDA 510(k) clearance or De Novo classification.	The company's initial focus is precisely on this indication [Columbia Entrepreneurship, Nov 2021], and the reported 96% gross margin model suggests a financially sustainable entry point [YouTube, Sep 2025].
Platform Expansion into Adjacent Cancers	Following initial clearance, the device gains indications for liver and bone metastases, becoming a multi-indication tool for interventional oncologists.	Publication of positive pilot study data in liver tumors, leveraging the same core electroporation mechanism.	The technology is described as targeting pancreatic, liver, and bone cancers from inception [Columbia Entrepreneurship, Nov 2021], implying a platform design, not a single-use device.

Data Accuracy: YELLOW -- The core opportunity thesis is based on company-stated focus areas and a reported partnership. The high-margin claim and specific growth catalysts lack third-party verification.

Sources

1. [Voyage Houston Magazine] Meet Dr. John Qiao of RadioClash | https://voyagehouston.com/interview/meet-john-qiao-m-d-of-radioclash-ltd-co/
2. [Columbia Entrepreneurship, Nov 2021] RadioClash Wins Columbia-CareOne Healthcare Innovation Challenge | https://entrepreneurship.columbia.edu/2021/11/19/radioclash-wins-columbia-careone-healthcare-innovation-challenge-2021-columbia-venture-competition/
3. [YouTube, Sep 2025] RadioClash Company Overview and CTO Interview | https://www.youtube.com/watch?v=undefined
4. [SignalBase] RadioClash Inc Secures $1M Seed Funding | https://www.leadsontrees.com/news/radioclash-inc-secures-1m-seed-funding
5. [Startup Columbia, 2022] General 1, Startup Columbia | https://www.startupcolumbia.org/fall-2022-competition
6. [The Org] Duane Bester - Founding Engineer at Handraise | https://theorg.com/org/handraise/org-chart/duane-bester
7. [BackTable] Dr. John Qiao on the BackTable VI Podcast | https://www.backtable.com/shows/vi/contributors/dr-john-qiao